300+ investors in your industry, stage, and region Get
Any industry
Google
Clean Energy
EdTech
Artificial Intelligence
Local
Enterprise Software
Travel
InsurTech
Platforms
Oil and Gas
Retail
Social Impact
Cryptocurrency
SaaS
Film
Restaurants
Photography
Payments
Email
CleanTech
Energy
Marketplace
Organic Food
Fitness
Machine Learning
Health Care
Agriculture (AgTech)
Gaming
Facebook
Social Network
Blockchain
B2B
Video Games
Big Data
Medical Device
Wellness
Education
Mobile
Automotive
Sports
Legal
eSports
Construction
Hospitality
Biotechnology
Consumer
Renewable Energy
Software
Crowdfunding
Venture Capital
Fashion
Social
Beauty
Infrastructure
Cannabis
Theatre
LGBT
Celebrity
Climate
Medical
Mobile Apps
Life Science
Wine and Spirits
Food and Beverage
Publishing
Music
Art
Real Estate
Sporting Goods
Manufacturing
Digital Media
FinTech
Finance
Financial Services
Social Media
Franchise
Mobile Advertising
Non Profit
Internet
Android
Sustainability
Hardware
Biotech
Impact
Proptech
Transportation
Enterprise
Community
Media (Entertainment)
Recruiting
Web3
Any country
Hong Kong
Thailand
United Arab Emirates
Egypt
Greece
Croatia
South Korea
Singapore
Brazil
Kyrgyzstan
LATAM
Africa
Oceania
Gibraltar
Liberia
Taiwan
Tunisia
Sweden
Zimbabwe
Zambia
Norway
Tajikistan
Mexico
Nigeria
Russian Federation
Togo
Guinea
Nepal
Iran
Isle of Man
Madagascar
Pakistan
Romania
Burkina Faso
Oman
Puerto Rico
Poland
Cameroon
Guernsey
Sudan
Andorra
Colombia
China
Armenia
Costa Rica
Czech Republic
Kenya
Kuwait
Marshall Islands
Luxembourg
Malta
Mozambique
Namibia
Mauritius
Nicaragua
Panama
Serbia
Uzbekistan
New Zealand
Australia
Saudi Arabia
Sri Lanka
Jamaica
Switzerland
Guatemala
Kazakhstan
Cayman Islands
Venezuela
Malawi
Myanmar
Uganda
Turkey
Uruguay
Morocco
Seychelles
Moldova
Botswana
Paraguay
Ireland
Japan
South Africa
France
Georgia
Denmark
Ghana
Iraq
Mali
Latvia
Malaysia
Portugal
Philippines
Sierra Leone
Rwanda
El Salvador
Senegal
Tanzania
Germany
India
Canada
United Kingdom
United States
Indonesia
Middle East
Dominican Republic
Bermuda
Asia
Albania
Spain
Angola
Europe
Cyprus
Qatar
Argentina
Bangladesh
Belgium
Barbados
Jordan
Austria
Ethiopia
Azerbaijan
Bulgaria
Ecuador
Bahamas
Faroe Islands
Estonia
Jersey
Bahrain
Bolivia
Algeria
Belize
Finland
Italy
Belarus
Hungary
Grenada
Israel
Iceland
Cambodia
Honduras
Lithuania
Liechtenstein
Lebanon
Mongolia
Peru
Slovenia
San Marino
Ukraine
Vietnam
Chile
Angel Investors
VC Funds
All Investors
Access Full Database - Free Forever
Open database
Federico Davini, Investment Board at A11 Venture

Federico Davini

Investment Board @ A11 Venture

Lucca, Italy

Federico Davini is a seed investor at A11 Venture in Lucca focused on Health Care and Biotechnology. Federico Davini - Investment Board @ A11 Venture

Total investments:
3
Last investment:
Lead investor:
33%

Last updated:

Industries Federico Davini invests in

Health CareBiotechnologyMedical Device

Stages Federico Davini invests in

Seed

Countries Federico Davini invests in

Italy

Investment Focus

Industry

  • Health Care 1 (33%)
  • Biotechnology 1 (33%)
  • Medical Device 1 (33%)

Investments

CompanyDescriptionRoundLinks
Neuron Guard Neuron Guard
Neuron Guard, recognized as the best European startup in HEALTH category (Startup Europe Awards - SEUA 2017), is developing a life-saving medical device that aims to become the standard of care for Targeted Temperature Management (TTM) therapy. Every 7 seconds around the world a person suffers of Acute Brain Damage because of CardiovascularDiseases (CVD) and Traumatic Brain Injury (TBI). They are the most costly and prevalent killers in the last 15 years (15 million deaths by CVD in 2015), and the leading cause of disability (the global incidence rate of TBI is 200 per 100k people per year). WHO estimated a global expenditure of $ 330 billion in 2015, but it is going to increase sharply: $ 4 trillion in 2025 - including premature death, disability, and health care costs - just for CVD in LMICs. Temperature is a vital body parameter. It regulates all cellular functions so its management is essential for the good outcome of patients in several medical conditions such as cardiac arrest, stroke, traumatic brain injury, neuro and cardiac surgery, epilepsy, migraine and oncology. Regulating body temperature at a desired level makes all other treatments more effective. The most modern medical approach is the target temperature management, where physicians try to maintain the most favourable temperature for the patient for up to 24-36 hours, preventing excessive warming (fever) or cooling.Our device is a targeted temperature management system composed by a THERAPEUTIC COLLAR POWERED BY A SMART CONTROL UNIT (the size of a small briefcase). The collar transforms the neck into a natural heat exchanger exploiting several physiological and anatomical characteristics of the human body. It is quicker to act on brain tissue but can also function as total body temperature adjusting device if required. A disposable protective shield makes cleaning the collar after each use simple while featuring an optimal safety profile both in term of pathogens and allergens. The control unit collects all the data of the treatment and transmits them to the Emergency Response System. Our mission is to improve the safety of patients on the roadside, at home or in the workplace, and to reduce the costs of chronic care. In fact, Neuron Guard aims to be the only device that can be used in every circumstance, inside and outside the hospital, and allow the user to fully manage the temperature of the patient warming and cooling as necessary. Our vision is to have a Neuron Guard kit in every public place just like the Automatic External Defibrillator (AED) to empower bystanders to immediately react in case of emergency. Under this perspective our device becomes a connected-intelligent platform that takes care of the patient, connects the scene with the Emergency Response System transmitting vital data to improve the readiness and effectiveness of professional intervention.The device is patented in Italy, USA and China. We have made several prototypes in collaboration with Italian and English companies, such as Tecno Elettra Impianti and TWI, tested it in laboratory and published the experimental results on the NeuroCritical Care Journal. We have also conducted a GAP Analysis with another English consulting firm (CDP) and we are testing the human prototype internally. We are seeking to raise 2.5M€ to complete the pre-industrialization, with design and construction of the human device for the pilot trial, finalized the regulatory clearance and launch it into the market in 2019. $635.3K / Seed / Nov 05, 2021
3dnextech 3dnextech
Soluzioni innovative per la stampa 3D, manifattura additiva, prototipazione rapida e trattamenti superficiali dei materiali plastici $278.1K / Seed / Jun 01, 2020
Neuron Guard Neuron Guard
Neuron Guard, recognized as the best European startup in HEALTH category (Startup Europe Awards - SEUA 2017), is developing a life-saving medical device that aims to become the standard of care for Targeted Temperature Management (TTM) therapy. Every 7 seconds around the world a person suffers of Acute Brain Damage because of CardiovascularDiseases (CVD) and Traumatic Brain Injury (TBI). They are the most costly and prevalent killers in the last 15 years (15 million deaths by CVD in 2015), and the leading cause of disability (the global incidence rate of TBI is 200 per 100k people per year). WHO estimated a global expenditure of $ 330 billion in 2015, but it is going to increase sharply: $ 4 trillion in 2025 - including premature death, disability, and health care costs - just for CVD in LMICs. Temperature is a vital body parameter. It regulates all cellular functions so its management is essential for the good outcome of patients in several medical conditions such as cardiac arrest, stroke, traumatic brain injury, neuro and cardiac surgery, epilepsy, migraine and oncology. Regulating body temperature at a desired level makes all other treatments more effective. The most modern medical approach is the target temperature management, where physicians try to maintain the most favourable temperature for the patient for up to 24-36 hours, preventing excessive warming (fever) or cooling.Our device is a targeted temperature management system composed by a THERAPEUTIC COLLAR POWERED BY A SMART CONTROL UNIT (the size of a small briefcase). The collar transforms the neck into a natural heat exchanger exploiting several physiological and anatomical characteristics of the human body. It is quicker to act on brain tissue but can also function as total body temperature adjusting device if required. A disposable protective shield makes cleaning the collar after each use simple while featuring an optimal safety profile both in term of pathogens and allergens. The control unit collects all the data of the treatment and transmits them to the Emergency Response System. Our mission is to improve the safety of patients on the roadside, at home or in the workplace, and to reduce the costs of chronic care. In fact, Neuron Guard aims to be the only device that can be used in every circumstance, inside and outside the hospital, and allow the user to fully manage the temperature of the patient warming and cooling as necessary. Our vision is to have a Neuron Guard kit in every public place just like the Automatic External Defibrillator (AED) to empower bystanders to immediately react in case of emergency. Under this perspective our device becomes a connected-intelligent platform that takes care of the patient, connects the scene with the Emergency Response System transmitting vital data to improve the readiness and effectiveness of professional intervention.The device is patented in Italy, USA and China. We have made several prototypes in collaboration with Italian and English companies, such as Tecno Elettra Impianti and TWI, tested it in laboratory and published the experimental results on the NeuroCritical Care Journal. We have also conducted a GAP Analysis with another English consulting firm (CDP) and we are testing the human prototype internally. We are seeking to raise 2.5M€ to complete the pre-industrialization, with design and construction of the human device for the pilot trial, finalized the regulatory clearance and launch it into the market in 2019. $720K / Seed / Dec 23, 2015

Co-Investors

CDP Venture Capital CDP Venture Capital 1 deal together
Fondo Rilancio Startup Fondo Rilancio Startup 1 deal together
A11 Venture

About A11 Venture

VC Fund · Lucca, Italy

A11-Venture investe nel capitale di startup innovative nei settori della robotica, automazione, meccatronica, cleantech, web e IT. Facilita la nascita e lo sviluppo di business innovativi globali per il futuro dell'economia locale. Contribuisce a costruire aziende, lavoro qualificato, brevetti, innovazione capaci di rilanciare e riportareinvestimenti e risorse sul territorio. I soci di A11 Venture credono fermamente nell’innovazione grazie a ciò è possibile crescere per linee esterne diversificando i propri investimenti, grazie ad un portafoglio di imprese, con una forte risk mitigation derivante dalla gestione professionale di tutti processi: scouting, team building, investimenti, management degli investimenti, accelerazione e disinvestimento.

A11 Venture Contacts

NameEmailPhoneSocials
Giovanni Polidori
Giovanni Polidori Founder & Investment Board
Liban Ahmed M Varetti
Liban Ahmed M Varetti Founder & Member of the Board of Investment
Federico Davini
Federico Davini Investment Board

Sign up to unlock verified contacts

Unlock Contacts

2 more contacts available

Open A11 Venture full profile

Access 48,091 investors

822 industries, 177 countries. Updated daily. Emails and phones included.

Browse database — It's Free!

Find investors for your startup

Search 48,091 investors by industry and country. Emails and phones included.

Any industry
Google
Clean Energy
EdTech
Artificial Intelligence
Local
Enterprise Software
Travel
InsurTech
Platforms
Oil and Gas
Retail
Social Impact
Cryptocurrency
SaaS
Film
Restaurants
Photography
Payments
Email
CleanTech
Energy
Marketplace
Organic Food
Fitness
Machine Learning
Health Care
Agriculture (AgTech)
Gaming
Facebook
Social Network
Blockchain
B2B
Video Games
Big Data
Medical Device
Wellness
Education
Mobile
Automotive
Sports
Legal
eSports
Construction
Hospitality
Biotechnology
Consumer
Renewable Energy
Software
Crowdfunding
Venture Capital
Fashion
Social
Beauty
Infrastructure
Cannabis
Theatre
LGBT
Celebrity
Climate
Medical
Mobile Apps
Life Science
Wine and Spirits
Food and Beverage
Publishing
Music
Art
Real Estate
Sporting Goods
Manufacturing
Digital Media
FinTech
Finance
Financial Services
Social Media
Franchise
Mobile Advertising
Non Profit
Internet
Android
Sustainability
Hardware
Biotech
Impact
Proptech
Transportation
Enterprise
Community
Media (Entertainment)
Recruiting
Web3
Any country
Hong Kong
Thailand
United Arab Emirates
Egypt
Greece
Croatia
South Korea
Singapore
Brazil
Kyrgyzstan
LATAM
Africa
Oceania
Gibraltar
Liberia
Taiwan
Tunisia
Sweden
Zimbabwe
Zambia
Norway
Tajikistan
Mexico
Nigeria
Russian Federation
Togo
Guinea
Nepal
Iran
Isle of Man
Madagascar
Pakistan
Romania
Burkina Faso
Oman
Puerto Rico
Poland
Cameroon
Guernsey
Sudan
Andorra
Colombia
China
Armenia
Costa Rica
Czech Republic
Kenya
Kuwait
Marshall Islands
Luxembourg
Malta
Mozambique
Namibia
Mauritius
Nicaragua
Panama
Serbia
Uzbekistan
New Zealand
Australia
Saudi Arabia
Sri Lanka
Jamaica
Switzerland
Guatemala
Kazakhstan
Cayman Islands
Venezuela
Malawi
Myanmar
Uganda
Turkey
Uruguay
Morocco
Seychelles
Moldova
Botswana
Paraguay
Ireland
Japan
South Africa
France
Georgia
Denmark
Ghana
Iraq
Mali
Latvia
Malaysia
Portugal
Philippines
Sierra Leone
Rwanda
El Salvador
Senegal
Tanzania
Germany
India
Canada
United Kingdom
United States
Indonesia
Middle East
Dominican Republic
Bermuda
Asia
Albania
Spain
Angola
Europe
Cyprus
Qatar
Argentina
Bangladesh
Belgium
Barbados
Jordan
Austria
Ethiopia
Azerbaijan
Bulgaria
Ecuador
Bahamas
Faroe Islands
Estonia
Jersey
Bahrain
Bolivia
Algeria
Belize
Finland
Italy
Belarus
Hungary
Grenada
Israel
Iceland
Cambodia
Honduras
Lithuania
Liechtenstein
Lebanon
Mongolia
Peru
Slovenia
San Marino
Ukraine
Vietnam
Chile
Angel Investors
VC Funds
All Investors

Similar Investors

Recommended lists

FAQ

What does Federico Davini invest in?

Federico Davini invests primarily in Health Care, Biotechnology and Medical Device startups, most often at Seed stage. Most of the 3 investments tracked by Shizune back companies in Italy. The Investment Focus section breaks down every industry, stage and country in the portfolio.

When did Federico Davini last invest?

The most recent investment recorded for Federico Davini closed in Nov 2021. Shizune tracks 3 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

Contact your first 100 investors today

Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.

Find investors — It's Free!
Federico Davini Federico Davini Find email